Future Science OA最新文献

{"title":"Comparative analysis of TPVB and ESPB for postoperative pain management in thoracic and breast surgeries.","authors":"Moeez Akram, Muhammad Rehan Iftikhar, Quratulain Fatima, Muhammad Ubaida, Hareem Khan, Hadia Mohsin, Muhammad Ibrahim, Muhammad Abdullah Hassan Wattoo, Muhammad Uzair Tahir, Marsad Ali","doi":"10.1080/20565623.2024.2430852","DOIUrl":"10.1080/20565623.2024.2430852","url":null,"abstract":"<p><strong>Objective: </strong>This meta-analysis assesses the efficacy and safety of erector spinae block (ESPB) and paravertebral block (PVB) for managing postoperative pain in thoracic and breast surgeries.</p><p><strong>Design: </strong>Data from 12 randomized controlled trials (RCTs) published between 2019 and 2022 were included, and selected based on stringent criteria.</p><p><strong>Setting: </strong>The RCTs were conducted across various clinical settings, including operating theaters worldwide.</p><p><strong>Patients: </strong>The analysis involved 844 patients undergoing thoracic or breast surgery under regional anesthesia, representing diverse health statuses.</p><p><strong>Interventions: </strong>Patients received either PVB or ESPB, typically guided by ultrasound, for postoperative pain control.</p><p><strong>Main findings: </strong>PVB demonstrated superior pain management during rest and mobility, requiring fewer additional analgesics than ESPB. Incidences of postoperative nausea and vomiting (PONV) and opioid consumption did not differ significantly between the methods. ESPB showed more effective block placement.</p><p><strong>Conclusion: </strong>PVB is preferred for reducing analgesic requirements and managing postoperative pain, especially during rest and activity. ESPB offers advantages in block placement. Surgical type and patient preferences should guide the choice between PVB and ESPB, necessitating further research for optimized clinical application.</p>","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"10 1","pages":"2430852"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11587851/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142692861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biologically active metabolites of <i>Alcaligenes faecalis:</i> diversity, statistical optimization, and future perspectives.","authors":"Sayed E El-Sayed, Neveen A Abdelaziz, Mohammad Y Alshahrani, Ghadir S El-Housseiny, Khaled M Aboshanab","doi":"10.1080/20565623.2024.2430452","DOIUrl":"10.1080/20565623.2024.2430452","url":null,"abstract":"<p><p><i>Alcaligenes faecalis</i> is a Gram-negative, rod-shaped bacterium that is common in the environment and has been reported to have various bioactive metabolites of industrial potential applications, including antifungal, antibacterial, antimycobacterial, antiparasitic, anticancer, antioxidant activities. In this review, we highlighted and discussed the respective metabolites, pointing out their chemical diversities, purification, current challenges, and future directions. <i>A. faecalis</i> has an industrial role in biodegradation, biosurfactants, and different enzyme production. In this review, the up-to-date various Response Surface Methodology methods (RSM) that can be employed for statistical optimization of the bioactive secondary metabolites have been discussed and highlighted, pointing out the optimal use of each method, current challenges, and future directions.</p>","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"10 1","pages":"2430452"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11789743/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142727152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A large gastric inflammatory fibroid polyp revealed by an upper gastrointestinal bleeding: a case report.","authors":"Ghada Gharbi, Manel Yakoubi, Asma Ben Mohamed, Moufida Mahmoudi, Mohamed Karim M'Farrej, Mahdi Bouassida, Amal Khsiba, Mouna Medhioub, Emna Chelbi, Lamine Hamzaoui","doi":"10.1080/20565623.2024.2431473","DOIUrl":"10.1080/20565623.2024.2431473","url":null,"abstract":"<p><p>Inflammatory fibroid polyps (IFPs) are rare submucosal lesions that usually arise in the stomach. It represents 0.1% of all gastric polypoid lesions and are frequently asymptomatic. It's usually revealed by an abdominal pain. Gastrointestinal bleeding can occur when the polyp is ulcerated. We report a case of a 72-year-old female with an IFP of the prepyloric region. The head of the polyp was thirty-five millimeters in diameter. It was revealed by an upper gastrointestinal bleeding and epigastric pain. An endoscopic resection was performed.</p>","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"10 1","pages":"2431473"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11587854/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142686562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Examining symptom and quality of life in polycystic ovarian syndrome: a web-based cross-sectional study.","authors":"Rukaiah Fatma Begum, Chitra Vellapandian, Sumithra Mohan","doi":"10.1080/20565623.2024.2430878","DOIUrl":"10.1080/20565623.2024.2430878","url":null,"abstract":"<p><strong>Background: </strong>Polycystic Ovarian Syndrome (PCOS) is a reproductive disorder that significantly impacts women's quality of life (QOL). Its unclear etiology, whether genetic or environmental, and the treatments associated with it have been widely studied globally.</p><p><strong>Research design and methods: </strong>This study assessed the QOL of 108 women with PCOS, examining both physical and mental symptoms. Participants completed the Short Form-12 (SF-12) questionnaire through a web-based survey to evaluate their QOL scores.</p><p><strong>Results: </strong>Common symptoms included menstrual irregularity (73.14%), hirsutism (65.7%), acne (62.03%), and obesity (22.22%). Complications such as diabetes mellitus (12.9%), hypertension (2.78%), infertility (1.85%), miscarriages (31.4%), hyperandrogenism (68.51%), and insulin resistance (28.7%) were reported. Patients with infertility had the lowest physical scores (PCS), while those working night shifts had the lowest mental scores (MCS).</p><p><strong>Conclusion: </strong>PCOS significantly affects QOL, with infertility contributing to the lowest physical scores and night shift work correlating with the lowest mental scores. These findings emphasize the need for integrated psychological and physical care, particularly for young working women with PCOS.</p>","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"10 1","pages":"2430878"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11581186/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DNA sequencing in oncology: a focus group study on a duty to recontact.","authors":"Noor A A Giesbertz, Lars S Assen, Wim H van Harten, Annelien L Bredenoord","doi":"10.1080/20565623.2024.2432233","DOIUrl":"10.1080/20565623.2024.2432233","url":null,"abstract":"<p><strong>Introduction: </strong>Particularly in genetics, former results can gain new meaning in the course of time. This raises questions about when professionals should recontact patients with new information. The aim of this focus group study is to clarify how different stakeholders in oncology think about the extent and limits of a duty to recontact.</p><p><strong>Materials and methods: </strong>One focus group with oncology patients (n = 12) and two groups with healthcare professionals (total n = 13) were conducted. In general, there was support for recontacting patients. The scope and extent of this duty was, however, perceived differently. Differences and similarities on the following six contextual factors are discussed: information features, costs and efforts, personal preferences, who is contacted, clinic or research setting, and time.</p><p><strong>Discussion: </strong>Oncology patients were clear in their wish to receive updates while the professionals were more hesitant to consider recontact as a standard of care. This is not surprising as recontacting patients with new information would mean a shift from a <i>patient-initiated</i> approach toward an <i>information-initiated</i> approach. This entails a different way of offering healthcare. Furthermore, the question is not only what professionals' responsibilities are, but how to design a system that complies with patients' wishes to receive updates.</p>","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"10 1","pages":"2432233"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11587842/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142692862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transforming Healthcare: The power and potential of digital medicine.","authors":"M Thirumal, S Monika","doi":"10.1080/20565623.2024.2430357","DOIUrl":"10.1080/20565623.2024.2430357","url":null,"abstract":"","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"10 1","pages":"2430357"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11587863/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142686675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hyperhomocysteinemia prevalence among patients with venous thromboembolism.","authors":"R Ben Salah, M Boudaya, S Fendri, R Marrekchi, Z Bahloul, K Jamoussi","doi":"10.1080/20565623.2024.2430417","DOIUrl":"10.1080/20565623.2024.2430417","url":null,"abstract":"<p><strong>Aims: </strong>The objectives of this study were to determine the plasma homocysteine (Hcy) levels and the prevalence of Hyperhomocysteinemia <b>(</b>HHC) in a group of Tunisian patients with deep vein thrombosis (DVT) by comparing it with healthy controls.</p><p><strong>Methods: </strong>it was an observational case-control study including patients hospitalized for the management of unprovoked DVT. For each subject, a routine biochemical assay was conducted, including plasma homocysteine measurement and determination of vitamin B12 and B9 levels, as these vitamins are essential for assessing hyperhomocysteinemia in DVT patients due to their role in regulating homocysteine.</p><p><strong>Results: </strong>We observed an increased mean plasma Hcy level compared to controls and the prevalence of Hyperhomocysteinemia 61.7% against 4% in the control subjects. The risk of developing DVT with HHC is 3.54.</p><p><strong>Conclusion: </strong>Our study found that homocysteine levels were higher in patients with DVT than in controls.</p>","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"10 1","pages":"2430417"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11581158/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Red cell distribution width-to-platelet ratio (RPR) as a predictor of prolonged stay at hospital for COVID-19 inpatients.","authors":"Martha Fors, Santiago J Ballaz","doi":"10.1080/20565623.2024.2432180","DOIUrl":"10.1080/20565623.2024.2432180","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Aims/background: &lt;/strong&gt;We looked at novel hematological composites like the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, red cell distribution width-to-lymphocyte ratio, red cell distribution width-to-platelet ratio, leukocyte-to-C reactive protein ratio, and lymphocyte-to-C reactive protein ratio as explanatory variables for COVID-19 patients´ hospital length of stay (LoS).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;The association of hematological indices with LoS was analyzed on 2930 COVID-19 patients using the univariate and multivariable Cox proportional hazards regression models with enter method. The Kaplan-Meier survival estimates were applied to LoS.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The survivors´ mean LoS was 7.8 ± 24.0 days, but the deaths´ mean LoS was 38.6 ± 41.9 days (W = 31338, p &lt; 0.01). Every hematological scores representative of the inflammatory status was significantly correlated in the univariate analysis with a prolonged LoS (p &lt; 0.001). In the multivariate analysis, it was discovered that just the monocyte-to-lymphocyte and lymphocyte-to-C reactive protein ratios had not achieved statistical significance. However, most systemic inflammation measures showed hazards ratios close to one. One exemption was the red cell distribution width-to-platelet ratio (RPR) index, which can increase the probability of a longer hospital stay by up to ten times (HR(IC95%) = 0.092(0.03-0.29); p &lt; 0.001).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;The most effective biomarker to identify COVID-19 patients at high risk for extended hospital stay was RPR.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Highlights: &lt;/strong&gt;&lt;b&gt;Introduction&lt;/b&gt;Determining hospital Length of Stay (LoS) is vital for resource management, especially for future COVID-19 outbreaks.Previous studies have primarily focused on sociodemographic and clinical attributes, along with resource availability, but have not accounted for other factors like routine laboratory tests, which can significantly impact LoS predictions.This study examines novel hematology scores as predictors of LoS, emphasizing their importance in resource-limited settings like Ecuador.&lt;b&gt;Methods&lt;/b&gt;This retrospective cohort study analyzed 2,930 COVID-19 patients admitted to Hospital IESS Quito Sur in Ecuador focusing on confirmed cases with complete blood count (CBC) values to assess LoS.The study explored various hematological ratios, such as the neutrophil-to-lymphocyte ratio (NLR) and red cell distribution width-to-lymphocyte ratio (RLR), as potential predictors of LoS and in-hospital outcomes for COVID-19 patients, using a combination of univariate and multivariable Cox proportional hazards regression models.Kaplan-Meier survival estimates and log-rank tests were used to analyze survival and discharge probabilities over time, highlighting sex-dependent effects and the significant association between selected hematological indices and patient outcomes.&lt;b&gt;Results&lt;/b&gt;The mean LoS for survivors was s","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"10 1","pages":"2432180"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11587840/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142686670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single nucleotide polymorphisms: impact on susceptibility to chemotherapy in patients with colorectal cancer.","authors":"M Angeles Vaz-Salgado, Victor Albarran, Javier Pozas, Reyes Ferreiro, Vanessa Pachón, Federico Longo, Mercedes Rodriguez, Emma Barreto, Julie Earl","doi":"10.1080/20565623.2024.2428077","DOIUrl":"10.1080/20565623.2024.2428077","url":null,"abstract":"<p><strong>Background: </strong>Single-nucleotide polymorphisms (SNPs) in enzyme-coding genes play a role in susceptibility to anti-cancer therapy.</p><p><strong>Materials & methods: </strong>A prospective study was performed of the relationship between enzyme activity and treatment response, drug toxicity and hypersensitivity reactions in 51 patients with colorectal cancer treated with fluoropyrimidine-based chemotherapy. SNP analysis was performed in 22 enzyme-coding genes with a previously described role in treatment efficacy.</p><p><strong>Results: </strong>SLC6 and MTHR enzyme activity was related with rates of progressive disease, GSTP1 activity with anti-EGFR antibodies-related skin toxicity, CYP3A5 and MTHR with chemotherapy dose reduction, CYP2B6, IL10, MTHR and TYMS activity with the risk of drug hypersensitivity reactions.</p><p><strong>Conclusion: </strong>Pharmacogenetics is a valuable predictive marker in oncology, related to chemotherapy treatment response, toxicity and hypersensitivity.</p>","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"10 1","pages":"2428077"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11587850/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142686672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the potential of Fargesin from <i>Chrysanthemum indicum</i> for chronic migraine: <i>in-silico</i> and pharmacokinetic study.","authors":"Rapuru Rushendran, Vellapandian Chitra","doi":"10.1080/20565623.2024.2428119","DOIUrl":"10.1080/20565623.2024.2428119","url":null,"abstract":"<p><strong>Introduction: </strong>Chronic migraine is recognized by the WHO as one of the most debilitating chronic conditions. It is primarily caused by central sensitization of the trigeminal nucleus caudalis. Key biomarkers associated with migraine include NFkB, IL-1β, CGRP, and iNOS. While CGRP antagonists have proven effective in treating migraines, Chrysanthemum indicum L., a traditional herbal remedy, has not been established as a treatment.</p><p><strong>Methods: </strong>To address this, we investigated whether Fargesin, a lignan found in CI, could potentially reduce migraines by targeting these biomarkers. We conducted pharmacokinetic, toxicological, and in-silico studies. Molecular docking studies revealed a strong interaction between Fargesin and CGRP/iNOS.</p><p><strong>Results: </strong>The pharmacokinetic analysis indicated robust intestinal absorption and effective penetration of the blood-brain barrier. In-silico toxicity assessments showed favorable results. Promising interactions with drug targets were observed in bioactivity tests.</p><p><strong>Conclusion: </strong>Fargesin from Chrysanthemum indicum may hold potential as a therapeutic agent for migraines.</p>","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"10 1","pages":"2428119"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11581172/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}